Early Briefing on Medical Appliances and Equipment Stocks - Amedica, Hologic, St. Jude Medical, AcelRx Pharma, and NuVasive

Jul 22, 2015, 09:00 ET from www.equityresearchinstitute.com

NEW YORK, July 22, 2015 /PRNewswire/ --

Equity Research Institute has initiated coverage on the following equities: Amedica Corporation (NASDAQ: AMDA), Hologic Inc. (NASDAQ: HOLX), St. Jude Medical Inc. (NYSE: STJ), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), and NuVasive Inc. (NASDAQ: NUVA). Free research report on Amedica can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=AMDA On Tuesday, July 21, 2015, the NASDAQ Composite ended at 5,208.12, down 0.21%, the Dow Jones Industrial Average declined 1.00%, to finish the day at 17,919.29, and the S&P 500 closed at 2,119.21, down 0.43%. The losses were broad based as seven out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.  

Amedica Corp.'s stock finished Tuesday's session 2.66% higher at $0.56. A total of 0.91 million shares were traded, which was much below its three months average volume of 4.47 million shares. Over the last one month and the previous three months, Amedica Corp.'s shares have surged 3.61% and 95.63%, respectively. However, the stock has declined 30.06% since the beginning of 2015. The company's shares are trading above their 50-day average by 32.55%. Amedica Corp.'s stock has a Relative Strength Index (RSI) of 54.69. Sign up and read the free notes on AMDA at:

https://www.EquityResearchInstitute.com/reports?keyword=AMDA

On Tuesday, shares in Hologic Inc. ended the session 0.01% lower at $37.90. The stock reported a trading volume of 1.34 million shares, below its three months average volume of 2.12 million shares. Shares of the company traded at a PE ratio of 92.43. Although, Hologic Inc.'s shares have lost 0.95% in the last one month, it has advanced 13.70% in the previous three months and 41.72% on YTD basis. The company is trading 3.06% above its 50-day moving average and 22.17% above its 200-day moving average. Moreover, shares of Hologic Inc. have an RSI of 52.03. The complimentary notes on HOLX can be downloaded in PDF format at:

https://www.EquityResearchInstitute.com/reports?keyword=HOLX

St. Jude Medical Inc.'s stock edged 0.18% higher, to close the day at $76.71. The stock recorded a trading volume of 3.83 million shares, much above its three months average volume of 1.49 million shares. Over the last one month and over the past three months, St. Jude Medical Inc.'s shares have gained 1.78% and 11.41%, respectively. Furthermore, the stock has advanced 18.95% since the start of this year. The company's shares are trading 3.40% above their 50-day moving average and 13.25% above their 200-day moving average. Additionally, St. Jude Medical Inc. traded at a PE ratio of 21.85 and has an RSI of 60.27. Register for free on Equity Research Institute and access the latest research on STJ at:

https://www.EquityResearchInstitute.com/reports?keyword=STJ

On Tuesday, shares in AcelRx Pharmaceuticals Inc. recorded a trading volume of 0.23 million shares, lower than their three months average volume of 0.61 million shares. The stock ended the day flat at $4.20. Although, AcelRx Pharmaceuticals Inc.'s stock has advanced 3.96% in the last one month, it has declined 8.10% in the previous three months and 37.59% on YTD basis. The company is trading above its 50-day moving average by 8.73%. Furthermore, shares of AcelRx Pharmaceuticals Inc. have an RSI of 56.02. The complete research on ACRX is available for free at:

https://www.EquityResearchInstitute.com/reports?keyword=ACRX

NuVasive Inc.'s stock edged 0.89% higher, to close Tuesday's session at $49.95. The stock recorded a trading volume of 0.42 million shares, below its three months average volume of 0.59 million shares. Over the last one month and the previous three months, NuVasive Inc.'s shares have advanced 0.58% and 15.41%, respectively. Additionally, the stock has gained 5.92% since the start of this year. The company is trading 3.09% and 10.53% above its 50-day and 200-day moving averages, respectively. Furthermore, NuVasive Inc.'s stock traded at a PE ratio of 78.05 and has an RSI of 61.34. Free in-depth research on NUVA is available at:

https://www.EquityResearchInstitute.com/reports?keyword=NUVA

--

About Equity Research Institute: 

Equity Research Institute ("ERI") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ERI has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ERI has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY 

ERI, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ERI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit www.equityresearchinstitute.com.

RESTRICTIONS 

ERI is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) equityresearchinstitute.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE www.equityresearchinstitute.com